Div. of Pharmacology, Metabolic and Vascular Diseases, Dept. of Internal Medicine, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands.
Life Sci. 2012 Apr 9;90(13-14):538-44. doi: 10.1016/j.lfs.2012.01.009. Epub 2012 Feb 1.
Besides acting as gastrointestinal prokinetic agents, 5-hydroxytryptamine(4) (5-HT(4)) receptor agonists can induce positive inotropism in human isolated atrium, but not in ventricles. We pharmacologically evaluated the gastroprokinetic 5-HT(4) receptor agonists tegaserod, prucalopride, R199715, cisapride, the cisapride metabolite norcisapride, and the 5-HT(3) receptor agonist MKC773 on human isolated myocardial trabeculae, and compared their effects with those induced by 5-HT and 5-methoxytryptamine (5-MeOT).
Atrial and ventricular trabeculae were paced and changes in contractile force were studied in the absence or presence of the 5-HT(4) receptor antagonist GR113808. Partial agonism was assessed using 5-HT(4) receptor agonists as antagonists against 5-HT. To test the contribution of L-type calcium channels, the inotropic responses to 5-HT and 5-MeOT were studied in the absence or presence of verapamil.
Like 5-HT and 5-MeOT, cisapride and tegaserod, but not prucalopride, R19971 and MKC-733, induced concentration-dependent positive inotropic responses on atrial trabeculae, which were abolished by GR113808. The L-type calcium channel blocker verapamil attenuated inotropic responses to 5-HT and 5-MeOT. None of the agonists affected the contraction of left ventricular trabeculae. Concentration response curves to 5-HT were shifted to the right in the presence of prucalopride, cisapride, tegaserod and R199715, but not MKC-773.
We conclude that (i) inotropic responses to 5-HT and 5-MeOT seem to depend on L-type calcium channels, (ii) tegaserod and cisapride behave as partial 5-HT(4) receptor agonists, while prucalopride, norcisapride and MKC-733 cause no significant effects on human atrial trabeculae, (iii) R199715 seems to behave as a 5-HT(4) receptor antagonist.
除了作为胃肠动力药物外,5-羟色胺(4)(5-HT(4))受体激动剂还可以在人体分离的心房中诱导正性变力作用,但不能在心室中诱导。我们对胃肠动力 5-HT(4)受体激动剂替扎司琼、普卡必利、R199715、西沙必利、西沙必利代谢产物诺西沙必利和 5-HT(3)受体激动剂 MKC773 对人体分离的心肌小梁进行了药理学评价,并将它们的作用与 5-HT 和 5-甲氧基色胺(5-MeOT)诱导的作用进行了比较。
心房和心室小梁被起搏,并在不存在或存在 5-HT(4)受体拮抗剂 GR113808 的情况下研究收缩力的变化。使用 5-HT(4)受体激动剂作为 5-HT 的拮抗剂来评估部分激动作用。为了测试 L 型钙通道的贡献,研究了 5-HT 和 5-MeOT 在不存在或存在维拉帕米的情况下对心肌小梁的变力反应。
与 5-HT 和 5-MeOT 一样,西沙必利和替扎司琼,但不是普卡必利、R19971 和 MKC-733,在心房小梁上诱导浓度依赖性的正性变力反应,这些反应被 GR113808 消除。L 型钙通道阻滞剂维拉帕米减弱了 5-HT 和 5-MeOT 的变力反应。没有一种激动剂影响左心室小梁的收缩。在普卡必利、西沙必利、替扎司琼和 R199715 的存在下,5-HT 的浓度反应曲线向右移位,但在 MKC-773 的存在下则没有。
(i)5-HT 和 5-MeOT 的变力反应似乎依赖于 L 型钙通道;(ii)替扎司琼和西沙必利表现为部分 5-HT(4)受体激动剂,而普卡必利、诺西沙必利和 MKC-733 对人体心房小梁没有显著作用;(iii)R199715 似乎表现为 5-HT(4)受体拮抗剂。